An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Simulations Plus to Participate in Upcoming Healthcare Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Simulations Plus, Inc. (SLP) will participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference virtually from February 13-14, 2024. CEO Shawn O’Connor will present on February 13 at 11:20 a.m. Eastern Time. The live webcast will be available for replay on the company's website.
Positive
None.
Negative
None.
LANCASTER, Calif.--(BUSINESS WIRE)--
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that it will participate in two healthcare conferences in February.
The Company will be presenting at Oppenheimer’s 34th Annual Healthcare Life Sciences Conference taking place virtually from February 13-14, 2024. Shawn O’Connor, chief executive officer, will be presenting on Tuesday, February 13, 2024, at 11:20 a.m. Eastern Time, and he will be meeting with investors throughout both days. The live webcast of the Company’s presentation can be accessed via this link and also on the Investors page of the Simulations Plus website where it will be available for replay following the event. For more information about the Oppenheimer Annual Healthcare Conference, or to register to attend, please visit the conference website.
The Company is also scheduled to host investor meetings at BTIG at Snowbird – BTIG’s 11th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference taking place at the Cliff Lodge in Snowbird, Utah. CEO Shawn O’Connor will be meeting one-on-one with institutional investors on Tuesday and Wednesday, February 13-14, 2024. The Company’s slide presentation will be available on the Investors page of the Simulations Plus website. For more information about the BTIG conference, please visit the BTIG website.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge artificial intelligence (AI)/machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our 2022 ESG update.
simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res